Biotoxtech Co., Ltd.
Financials
Valuation Metrics
Biotoxtech Co., Ltd.'s Market Cap is ₩339B. At end of 2025 it was ₩449B. Ranked #1955 of 2,405 in KR market (top 81%), #1223 of 1,627 on KOSDAQ (top 75%), #208 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 33.91B KRW | KR#1,955/2,405 Sec#208/231 |
| Revenue | 52.48B KRW | KR#1,750/2,405 Sec#119/231 |
| Net Income | -7.12B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 132.35B KRW | KR#1,589/2,405 Sec#124/231 |
| Net Assets | 22.38B KRW | KR#2,253/2,405 Sec#212/231 |
| Employees | 230 | KR#991/2,405 Sec#83/231 |
| Value | ||
| P/B | 1.51x | KR#1,823/2,405 Sec#128/231 |
| P/S | 0.65x | KR#1,144/2,405 Sec#55/231 |
| FCF Yield | 13.32% | KR#538/2,405 Sec#17/231 |
| Profitability | ||
| ROE | -31.81% | KR#2,187/2,405 Sec#179/231 |
| ROA | -5.38% | KR#1,944/2,405 Sec#141/231 |
| Op. Margin | -6.60% | KR#1,905/2,405 Sec#126/231 |
| Revenue Growth | 20.88% | KR#527/2,405 Sec#49/231 |
| Financial Health | ||
| Debt Ratio | 491.29% | KR#2,310/2,405 Sec#226/231 |
| Total Debt | 41.50B KRW | KR#1,074/2,405 Sec#74/231 |
| FCF | 4.52B KRW | KR#924/2,405 Sec#64/231 |
| Cash | 14.85B KRW | KR#1,436/2,405 Sec#114/231 |
| Current Ratio | 0.54x | KR#2,105/2,405 Sec#203/231 |
| Performance | ||
| 1Y Return | -21.44% | KR#1,175/2,405 Sec#85/231 |
| 1M Return | -6.59% | KR#863/2,405 Sec#80/231 |
| From 52W High | -48.36% | KR#1,093/2,405 Sec#81/231 |
| 1Y MDD | -49.48% | KR#931/2,405 Sec#73/231 |
| Trading | ||
| Volume | 25,210 shares | KR#1,375/2,405 Sec#132/231 |
| Trading Value | 53.0M KRW | KR#1,696/2,405 Sec#180/231 |
| Foreign Own. | 2.15% | KR#1,569/2,405 Sec#151/231 |
| Per Share | ||
| EPS | -446 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,403 KRW | KR#2,217/2,405 Sec#194/231 |
Company Info
The company, a non-clinical CRO specialist listed on KOSDAQ in 2007, owns the subsidiary KiforPrime Research. It performs toxicity, safety, and efficacy evaluations for medicines, cell therapies, gene therapies, and chemicals, providing professional contract research services through GLP certification. In line with global industry trends, the company is expanding primate non-clinical trials and pursuing innovation by establishing experimental animal facilities and offering consulting services. Biotoxtech was established in 2000 and is headquartered in Chungcheongbuk-do, Cheongju-si.